Results 211 to 220 of about 150,306 (248)

Real-World Long-Term Outcomes of Rezūm Therapy for Large-Volume Benign Prostatic Hyperplasia: A Multicenter Cohort Study. [PDF]

Low Urin Tract Symptoms
Liu L, Siqueira MHB, Bhojani N, Chughtai B, Zorn KC, Cindolo L, Ferrari G, Lajkosz K, Fields E, Elterman D.   +9 more
europepmc   +1 more source

Prostate morcellation devices: a systematic review and meta‐analysis of clinical outcomes and efficiency

BJU International, Volume 138, Issue 4, Page 537-548, October 2026.
Objective To systematically evaluate the efficiency and safety of different prostate morcellators used during prostate enucleation for benign prostatic hyperplasia (BPH). Methods A systematic review was performed according to the Preferred Reporting Items for Systematic Review and Meta‐analyses guidelines.
Stessy Kutchukian, Pietro Scilipoti, Mikael Abi Abdallah, Astrid La Rosa, Tristan Filler, Frédéric Panthier, Marie Chicaud, Stefano Moretto, Steeve Doizi   +8 more
wiley   +1 more source

Detection of benign prostatic hyperplasia using RGB prostate images and deep learning. [PDF]

Sci Rep
Srivastava R, Kumar R, Kant S, Shakya HK.   +3 more
europepmc   +1 more source

Trends in kidney stone disease: a 5‐year update of stone management in England and Scotland

BJU International, Volume 138, Issue 4, Page 620-629, October 2026.
Objectives To describe contemporary trends in kidney stone disease (KSD)‐related inpatient episodes, procedures, and costs in England and Scotland, with emphasis on post‐coronavirus disease 2019 (COVID‐19) service recovery, socioeconomic variation in Scotland, comparison with other urological procedures, and 10‐year healthcare demand and cost ...
Catherine E. Lovegrove, Robert Geraghty, Imran Ahmad, Hing Y. Leung, Ben Turney   +4 more
wiley   +1 more source

Integrated Single-Cell and Bulk RNA Sequencing Reveals Inflammatory Microenvironment and Glycolysis-Driven Epithelial Proliferation in Benign Prostatic Hyperplasia. [PDF]

J Inflamm Res
Ge J, Jiao W, Yu W, Shi G, Wang X, Zhang J.   +5 more
europepmc   +1 more source

Mechanism of Qianlie Zhitong Formula Against Chronic Prostatitis Based on Proteomics and Metabolomics

Chemical Biology &Drug Design, Volume 108, Issue 4, October 2026.
QLZTF blood‐absorbed bioactive components (hydroxysafflor yellow A, saikosaponin A and D) activate two core metabolic pathways (pantothenic acid and CoA biosynthesis, BCAA degradation) in prostatic epithelial cells. This suppresses ferroptosis and the secretion of pro‐inflammatory IL‐17/IFN‐γ, thereby ameliorating prostatic edema, interstitial fibrosis,
Lidan Dong, Linhan Chang, Caijia Song, Jialin Yan, Tiantong Shen, Zhen Ding, Yunyu Liu, Chenglong Zheng, Yanfei Zheng, Qi Wang   +9 more
wiley   +1 more source

Effects of <i>Serenoa repens</i> extract on sexual function in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. [PDF]

Sex Med
Dong C, Zheng J, Jiang Y.
europepmc   +1 more source

Association of Three HIF‐1α Genotypes With Susceptibility and Severity of Chronic Kidney Disease

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Hypoxic signaling is a critical factor in the pathogenesis of Chronic Kidney Disease (CKD). Hypoxia‐Inducible Factor 1 (HIF‐1) is a transcription factor that is highly expressed in the kidney and is associated with renal tubular hypoxic adaptation. Variation in the HIF‐1α subunit gene has been associated with renal pathologies.
Hanifa Aktar, Shahrzad Ashena, Mohammad Sanaei Ardekani, Shahrzad Movafagh   +3 more
wiley   +1 more source

Minimally invasive treatments for benign prostatic hyperplasia: A narrative review. [PDF]

Medicine (Baltimore)
Zhang X, Liang T, Dong Y, Gao H.
europepmc   +1 more source